Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 670691, 13 pages
http://dx.doi.org/10.1155/2015/670691
Review Article

Statistical Methods for Establishing Personalized Treatment Rules in Oncology

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Unit 1411, 1400 Pressler Street, Houston, TX 77030, USA

Received 25 November 2014; Accepted 9 February 2015

Academic Editor: Aurelio Ariza

Copyright © 2015 Junsheng Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Reimand, O. Wagih, and G. D. Bader, “The mutational landscape of phosphorylation signaling in cancer,” Scientific Reports, vol. 3, article 2651, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Simon, “Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology,” Personalized Medicine, vol. 7, no. 1, pp. 33–47, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. P. L. Bedard, A. R. Hansen, M. J. Ratain, and L. L. Siu, “Tumour heterogeneity in the clinic,” Nature, vol. 501, no. 7467, pp. 355–364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. M. D. Pegram, G. Pauletti, and D. J. Slamon, “Her-2/neu as a predictive marker of response to breast cancer therapy,” Breast Cancer Research and Treatment, vol. 52, no. 1–3, pp. 65–77, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. G. J. Kelloff and C. C. Sigman, “Cancer biomarkers: selecting the right drug for the right patient,” Nature Reviews Drug Discovery, vol. 11, no. 3, pp. 201–214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. J. A. DiMasi, J. M. Reichert, L. Feldman, and A. Malins, “Clinical approval success rates for investigational cancer drugs,” Clinical Pharmacology and Therapeutics, vol. 94, no. 3, pp. 329–335, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Hay, D. W. Thomas, J. L. Craighead, C. Economides, and J. Rosenthal, “Clinical development success rates for investigational drugs,” Nature Biotechnology, vol. 32, no. 1, pp. 40–51, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. S. S. Knox, “From ‘omics’ to complex disease: a systems biology approach to gene-environment interactions in cancer,” Cancer Cell International, vol. 10, article 11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Deschoolmeester, M. Baay, P. Specenier, F. Lardon, and J. B. Vermorken, “A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy,” The Oncologist, vol. 15, no. 7, pp. 699–731, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. Sosman, K. B. Kim, L. Schuchter et al., “Survival in braf V600–mutant advanced melanoma treated with vemurafenib,” The New England Journal of Medicine, vol. 366, no. 8, pp. 707–714, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Paik, S. Shak, G. Tang et al., “A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer,” The New England Journal of Medicine, vol. 351, no. 27, pp. 2817–2826, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. K. S. Albain, W. E. Barlow, S. Shak et al., “Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial,” The Lancet Oncology, vol. 11, no. 1, pp. 55–65, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. E. Lang, J. S. Wecsler, M. F. Press, and D. Tripathy, “Molecular markers for breast cancer diagnosis, prognosis and targeted therapy,” Journal of Surgical Oncology, vol. 111, no. 1, pp. 81–90, 2015. View at Publisher · View at Google Scholar
  15. W. Werft, A. Benner, and A. Kopp-Schneider, “On the identification of predictive biomarkers: detecting treatment-by-gene interaction in high-dimensional data,” Computational Statistics and Data Analysis, vol. 56, no. 5, pp. 1275–1286, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Jenkins, A. Flynn, T. Smart et al., “A statistician's perspective on biomarkers in drug development,” Pharmaceutical Statistics, vol. 10, no. 6, pp. 494–507, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. A. J. Vickers, M. W. Kattan, and D. J. Sargent, “Method for evaluating prediction models that apply the results of randomized trials to individual patients,” Trials, vol. 8, no. 1, article 14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Janes, M. S. Pepe, P. M. Bossuyt, and W. E. Barlow, “Measuring the performance of markers for guiding treatment decisions,” Annals of Internal Medicine, vol. 154, no. 4, pp. 253–259, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. DeRubeis, Z. D. Cohen, N. R. Forand, J. C. Fournier, L. A. Gelfand, and L. Lorenzo-Luaces, “The personalized advantage index: translating research on prediction into individualized treatment recommendations. A demonstration,” PLoS ONE, vol. 9, no. 1, Article ID e83875, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. D. P. Byar and D. K. Corle, “Selecting optimal treatment in clinical trials using covariate information,” Journal of Chronic Diseases, vol. 30, no. 7, pp. 445–459, 1977. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Thatcher, A. Chang, P. Parikh et al., “Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer),” The Lancet, vol. 366, no. 9496, pp. 1527–1537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. J. Vickers, “Prediction models in cancer care,” CA: A Cancer Journal for Clinicians, vol. 61, no. 5, pp. 315–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. R. M. Simon, “Subgroup analysis,” in Wiley Encyclopedia of Clinical Trials, John Wiley & Sons, Hoboken, NJ, USA, 2007. View at Google Scholar
  24. S. J. Pocock, S. E. Assmann, L. E. Enos, and L. E. Kasten, “Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems,” Statistics in Medicine, vol. 21, no. 19, pp. 2917–2930, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. P. M. Rothwell, Z. Mehta, S. C. Howard, S. A. Gutnikov, and C. P. Warlow, “From subgroups to individuals: general principles and the example of carotid endarterectomy,” The Lancet, vol. 365, no. 9455, pp. 256–265, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Wang, S. W. Lagakos, J. H. Ware, D. J. Hunter, and J. M. Drazen, “Statistics in medicine—reporting of subgroup analyses in clinical trials,” The New England Journal of Medicine, vol. 357, no. 21, pp. 2108–2194, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. International Breast Cancer Study Group, “Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial,” Journal of the National Cancer Institute, vol. 94, no. 14, pp. 1054–1065, 2002. View at Publisher · View at Google Scholar
  28. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), “Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials,” The Lancet, vol. 365, no. 9472, pp. 1687–1717, 2005. View at Publisher · View at Google Scholar
  29. F. E. Harrell, K. L. Lee, and D. B. Mark, “Tutorial in biostatistics multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors,” Statistics in Medicine, vol. 15, no. 4, pp. 361–387, 1996. View at Google Scholar
  30. S. Gill, C. L. Loprinzi, D. J. Sargent et al., “Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1797–1806, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Qian and S. A. Murphy, “Performance guarantees for individualized treatment rules,” The Annals of Statistics, vol. 39, no. 2, pp. 1180–1210, 2011. View at Publisher · View at Google Scholar · View at MathSciNet
  32. W. Lu, H. H. Zhang, and D. Zeng, “Variable selection for optimal treatment decision,” Statistical Methods in Medical Research, vol. 22, no. 5, pp. 493–504, 2013. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  33. R. Kohavi, “A study of cross-validation and bootstrap for accuracy estimation and model selection,” in Proceedings of the 14th International Joint Conference on Artificial Intelligence (IJCAI '95), vol. 2, pp. 1137–1145, 1995.
  34. E. W. Steyerberg, A. J. Vickers, N. R. Cook et al., “Assessing the performance of prediction models: a framework for traditional and novel measures,” Epidemiology, vol. 21, no. 1, pp. 128–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. P. R. Rosenbaum and D. B. Rubin, “The central role of the propensity score in observational studies for causal effects,” Biometrika, vol. 70, no. 1, pp. 41–55, 1983. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  36. R. B. d'Agostino Jr., “Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group,” Statistics in Medicine, vol. 17, no. 19, pp. 2265–2281, 1998. View at Publisher · View at Google Scholar
  37. R. Pazdur, “Endpoints for assessing drug activity in clinical trials,” The Oncologist, vol. 13, supplement 2, pp. 19–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. S. L. Spruance, J. E. Reid, M. Grace, and M. Samore, “Hazard ratio in clinical trials,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 8, pp. 2787–2792, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. J. D. Kalbeisch and R. L. Prentice, The Statistical Analysis of Failure Time Data, vol. 360, John Wiley & Sons, 2011.
  40. Y. Geng, Flexible Statistical Learning Methods for Survival Data: Risk Prediction and Optimal Treatment Decision, North Carolina State University, 2013. View at MathSciNet
  41. J. Li, L. Zhao, L. Tian et al., A Predictive Enrichment Procedure to Identify Potential Responders to a New Therapy for Randomized, Comparative, Controlled Clinical Studies, Harvard University Biostatistics Working Paper Series, Working Paper 169, Harvard University, 2014.
  42. C. Kang, H. Janes, and Y. Huang, “Combining biomarkers to optimize patient treatment recommendations,” Biometrics, vol. 70, no. 3, pp. 695–720, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Zhang, A. A. Tsiatis, E. B. Laber, and M. Davidian, “A robust method for estimating optimal treatment regimes,” Biometrics, vol. 68, no. 4, pp. 1010–1018, 2012. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  44. B. Zhang, A. A. Tsiatis, M. Davidian, M. Zhang, and E. Laber, “Estimating optimal treatment regimes from a classification perspective,” Stat, vol. 1, no. 1, pp. 103–114, 2012. View at Google Scholar
  45. J. C. Foster, J. M. G. Taylor, and S. J. Ruberg, “Subgroup identification from randomized clinical trial data,” Statistics in Medicine, vol. 30, no. 24, pp. 2867–2880, 2011. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  46. US Food and Drug Administration, Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics, US Food and Drug Administration, Washington, DC, USA, 2007.
  47. H. Janes, M. D. Brown, M. Pepe, and Y. Huang, “Statistical methods for evaluating and comparing biomarkers for patient treatment selection,” UW Biostatistics Working Paper Series, Working Paper 389, 2013. View at Google Scholar
  48. R Development Core Team, R: a language and environment for statistical computing, 2008, http://www.R-project.org/.
  49. X.-J. Ma, Z. Wang, P. D. Ryan et al., “A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen,” Cancer Cell, vol. 5, no. 6, pp. 607–616, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. X.-J. Ma, S. G. Hilsenbeck, W. Wang et al., “The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer,” Journal of Clinical Oncology, vol. 24, no. 28, pp. 4611–4619, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. D. C. Sgroi, E. Carney, E. Zarrella et al., “Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker,” Journal of the National Cancer Institute, vol. 105, no. 14, pp. 1036–1042, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. M. S. Cepeda, R. Boston, J. T. Farrar, and B. L. Strom, “Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders,” The American Journal of Epidemiology, vol. 158, no. 3, pp. 280–287, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. P. C. Austin, “An introduction to propensity score methods for reducing the effects of confounding in observational studies,” Multivariate Behavioral Research, vol. 46, no. 3, pp. 399–424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Heinze and P. Jüni, “An overview of the objectives of and the approaches to propensity score analyses,” European Heart Journal, vol. 32, no. 14, Article ID ehr031, pp. 1704–1708, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. L. E. Braitman and P. R. Rosenbaum, “Rare outcomes, common treatments: analytic strategies using propensity scores,” Annals of Internal Medicine, vol. 137, no. 8, pp. 693–695, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. D. M. Witten and R. Tibshirani, “Survival analysis with high-dimensional covariates,” Statistical Methods in Medical Research, vol. 19, no. 1, pp. 29–51, 2010. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  57. A. E. Hoerl and R. W. Kennard, “Ridge regression: biased estimation for nonorthogonal problems,” Technometrics, vol. 42, no. 1, pp. 80–86, 2000. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Tibshirani, “Regression shrinkage and selection via the lasso,” Journal of the Royal Statistical Society. Series B. Methodological, vol. 58, no. 1, pp. 267–288, 1996. View at Google Scholar · View at MathSciNet
  59. H. Zou, “The adaptive lasso and its oracle properties,” Journal of the American Statistical Association, vol. 101, no. 476, pp. 1418–1429, 2006. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  60. B. Efron, T. Hastie, I. Johnstone, and R. Tibshirani, “Least angle regression,” The Annals of Statistics, vol. 32, no. 2, pp. 407–499, 2004. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  61. T. Hastie and B. Efron, “lars: Least angle regression, lasso and forward stagewise,” R package version 1.2, 2013, http://cran.r-project.org/web/packages/lars/index.html.
  62. J. Fan and R. Li, “Variable selection via nonconcave penalized likelihood and its oracle properties,” Journal of the American Statistical Association, vol. 96, no. 456, pp. 1348–1360, 2001. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  63. H. Zou and T. Hastie, “Regularization and variable selection via the elastic net,” Journal of the Royal Statistical Society. Series B. Statistical Methodology, vol. 67, no. 2, pp. 301–320, 2005. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  64. N. Krämer, J. Schäfer, and A.-L. Boulesteix, “Regularized estimation of large-scale gene association networks using graphical gaussian models,” BMC Bioinformatics, vol. 10, no. 1, article 384, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Breheny and J. Huang, “Coordinate descent algorithms for nonconvex penalized regression, with applications to biological feature selection,” The Annals of Applied Statistics, vol. 5, no. 1, pp. 232–253, 2011. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  66. S. M. Hammer, D. A. Katzenstein, M. D. Hughes et al., “A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter,” The New England Journal of Medicine, vol. 335, no. 15, pp. 1081–1090, 1996. View at Publisher · View at Google Scholar · View at Scopus
  67. H. M. Bøvelstad, S. Nygård, H. L. Størvold et al., “Predicting survival from microarray data—a comparative study,” Bioinformatics, vol. 23, no. 16, pp. 2080–2087, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. V. Kehl and K. Ulm, “Responder identification in clinical trials with censored data,” Computational Statistics and Data Analysis, vol. 50, no. 5, pp. 1338–1355, 2006. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Royston and M. K. Parmar, “The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt,” Statistics in Medicine, vol. 30, no. 19, pp. 2409–2421, 2011. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  70. P. Royston and M. K. B. Parmar, “Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome,” BMC Medical Research Methodology, vol. 13, no. 1, article 152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. E. T. Lee and J. W. Wang, Statistical Methods for Survival Data Analysis, John Wiley & Sons, Hoboken, NJ, USA, 2013.
  72. Y. Zhao, D. Zeng, A. J. Rush, and M. R. Kosorok, “Estimating individualized treatment rules using outcome weighted learning,” Journal of the American Statistical Association, vol. 107, no. 499, pp. 1106–1118, 2012. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  73. D. B. Rubin and M. J. van der Laan, “Statistical issues and limitations in personalized medicine research with clinical trials,” The International Journal of Biostatistics, vol. 8, no. 1, pp. 1–20, 2012. View at Google Scholar · View at Scopus
  74. L. Breiman, “Random forests,” Machine Learning, vol. 45, no. 1, pp. 5–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Friedman, T. Hastie, and R. Tibshirani, “Additive logistic regression: a statistical view of boosting,” The Annals of Statistics, vol. 28, no. 2, pp. 337–407, 2000. View at Publisher · View at Google Scholar · View at MathSciNet
  76. C. Cortes and V. Vapnik, “Support-vector networks,” Machine Learning, vol. 20, no. 3, pp. 273–297, 1995. View at Publisher · View at Google Scholar · View at Scopus
  77. L. Breiman, J. Friedman, C. J. Stone, and R. A. Olshen, Classification and Regression Trees, CRC Press, New York, NY, USA, 1984.
  78. S. Dudoit, J. Fridlyand, and T. P. Speed, “Comparison of discrimination methods for the classification of tumors using gene expression data,” Journal of the American Statistical Association, vol. 97, no. 457, pp. 77–87, 2002. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  79. A. Liaw and M. Wiener, “Classification and regression by randomforest,” R News, vol. 2, no. 3, pp. 18–22, 2002, http://CRAN.R-project.org/doc/Rnews/. View at Google Scholar
  80. T. Therneau, B. Atkinson, and B. Ripley, “rpart: Recursive Partitioning and Regression Trees,” R package version 4.1-3, http://cran.r-project.org/web/packages/rpart/index.html.
  81. A. Kapelner, J. Bleich, Z. D. Cohen, R. J. DeRubeis, and R. Berk, “Inference for treatment regime models in personalized medicine,” http://arxiv.org/abs/1404.7844.
  82. X. Song and M. S. Pepe, “Evaluating markers for selecting a patient's treatment,” Biometrics, vol. 60, no. 4, pp. 874–883, 2004. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  83. T. Karrison, “Restricted mean life with adjustment for covariates,” Journal of the American Statistical Association, vol. 82, no. 400, pp. 1169–1176, 1987. View at Publisher · View at Google Scholar · View at MathSciNet
  84. C. Barker, “The mean, median, and confidence intervals of the kaplan-meier survival estimate—computations and applications,” Journal of the American Statistical Association, vol. 63, no. 1, pp. 78–80, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. B. Efron and R. J. Tibshirani, An Introduction to the Bootstrap, vol. 57, CRC Press, 1994.
  86. S. Arlot and A. Celisse, “A survey of cross-validation procedures for model selection,” Statistics Surveys, vol. 4, pp. 40–79, 2010. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  87. A. Kapelner and J. Bleich, “PTE: Personalized Treatment Evaluator,” 2014, R package version 1.0, http://CRAN.R-project.org/package=PTE.
  88. S. A. Murphy, “Optimal dynamic treatment regimes,” Journal of the Royal Statistical Society, Series B: Statistical Methodology, vol. 65, no. 2, pp. 331–355, 2003. View at Publisher · View at Google Scholar · View at MathSciNet · View at Scopus
  89. J. M. Robins, “Optimal structural nested models for optimal sequential decisions,” in Proceedings of the Second Seattle Symposium in Biostatistics, vol. 179 of Lecture Notes in Statistics, pp. 189–326, Springer, Berlin, Germany, 2004. View at Publisher · View at Google Scholar
  90. Y. Zhao and D. Zeng, “Recent development on statistical methods for personalized medicine discovery,” Frontiers of Medicine in China, vol. 7, no. 1, pp. 102–110, 2013. View at Publisher · View at Google Scholar · View at Scopus